About gyre therapeutics inc - GYRE
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
GYRE At a Glance
Gyre Therapeutics, Inc.
12770 High Bluff Drive
San Diego, California 92130
| Phone | 1-619-949-3681 | Revenue | 116.59M | |
| Industry | Pharmaceuticals: Major | Net Income | 5.03M | |
| Sector | Health Technology | 2025 Sales Growth | 10.241% | |
| Fiscal Year-end | 12 / 2026 | Employees | 625 | |
| View SEC Filings |
GYRE Valuation
| P/E Current | 316.444 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 313.778 |
| Price to Sales Ratio | 6.248 |
| Price to Book Ratio | 6.08 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 50.904 |
| Enterprise Value to Sales | 6.117 |
| Total Debt to Enterprise Value | 0.001 |
GYRE Efficiency
| Revenue/Employee | 186,540.80 |
| Income Per Employee | 8,043.20 |
| Receivables Turnover | 3.156 |
| Total Asset Turnover | 0.80 |
GYRE Liquidity
| Current Ratio | 5.598 |
| Quick Ratio | 5.042 |
| Cash Ratio | 2.867 |
GYRE Profitability
| Gross Margin | 95.355 |
| Operating Margin | 9.856 |
| Pretax Margin | 12.382 |
| Net Margin | 4.312 |
| Return on Assets | 3.449 |
| Return on Equity | 5.937 |
| Return on Total Capital | 4.699 |
| Return on Invested Capital | 5.895 |
GYRE Capital Structure
| Total Debt to Total Equity | 0.886 |
| Total Debt to Total Capital | 0.878 |
| Total Debt to Total Assets | 0.565 |
| Long-Term Debt to Equity | 0.286 |
| Long-Term Debt to Total Capital | 0.283 |